Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
111. |
ECCT/24/08/01 | Evaluate clearance of HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Kevin Makori Gesimba Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Victoria Cancer Care and Research centre (Nyamira county) |
16-10-2024 |
View |
112. |
ECCT/24/06/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Raymond Scott McClelland Site(s) in Kenya 1. Pwani Research Centre (Mombasa county) |
02-07-2024 |
View |
113. |
ECCT/24/06/02 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jesse Gitaka Site(s) in Kenya 1. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 2. Clinical Research Health Network (CREA-N) (Machakos county) 3. KEMRI-Mtwapa Clinical Annex (Kilifi county) 4. University of Nairobi Clinical Research Centre (Nairobi City county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
25-11-2024 |
View |
114. |
ECCT/24/05/06 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) - Kisumu (Kisumu county) |
27-05-2024 |
View |
115. |
ECCT/24/05/05 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Kariuki Simon Kariuki 2. Patricia Odero Ojwang Site(s) in Kenya 1. Kenya Medical Research Institute-Dr Kariuki (Kisumu county) |
29-08-2024 |
View |
116. |
ECCT/24/05/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county) |
08-05-2024 |
View |
117. |
ECCT/24/05/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya 1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county) |
08-05-2024 |
View |
118. |
ECCT/24/04/08 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Wilson Muraya Site(s) in Kenya 1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county) |
08-05-2024 |
View |
119. |
ECCT/24/04/07 | FORMATIVE-PEARLS TRIAL PEARLS FORMATIVE (Preventing pre-eclampsia: Evaluating AspiRin Low-dose regimens following risk Screening) |
Principal Investigator(s) 1. Zahida Qureshi 2. Alfred Osoti 3. George Gwako 4. Rosa Chemwey Site(s) in Kenya 1. Kakamega General County Teaching and Referral Hospital (Kakamega county) 2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 3. Kiambu Level 5 Hospital (Kiambu county) 4. Kisii Teaching and Referral Hospital (Kisii county) 5. Meru Teaching and Referral Hospital (Meru county) |
05-07-2024 |
View |
120. |
ECCT/24/04/03 | SMAART-MAP trial Severe Malaria A Research and Trials consortium - Multisite Adaptive Platform trial |
Principal Investigator(s) 1. Prof Kathryn Maitland Maitland Site(s) in Kenya Kilifi County Hospital |
29-08-2024 |
View |